A Slow-Digesting, Low-Glycemic Load Nutritional Beverage Improves Glucose Tolerance in Obese Pregnant Women Without Gestational Diabetes by Maitland, Rahat et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1089/dia.2018.0102
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Maitland, R., Patel, N., Barr, S., Sherry, C., Marriage, B., Seed, P., ... Poston, L. (2018). A Slow-Digesting, Low-
Glycemic Load Nutritional Beverage Improves Glucose Tolerance in Obese Pregnant Women Without
Gestational Diabetes. Diabetes Technology and Therapeutics, 20(10), 672-680.
https://doi.org/10.1089/dia.2018.0102
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
A Slow-Digesting, Low-Glycaemic Load (SD-LGL) Nutritional Beverage 1 
improves glucose tolerance in obese pregnant women without Gestational 2 
Diabetes 3 
 4 
Rahat Maitland MBChB1, Nashita Patel MBBS1, Suzanne Barr PhD1, Christina 5 
Sherry PhD, RD, MBA2, Barbara Marriage PhD, RD2, Paul Seed MSc1, 6 
Llenalia Garcia Fernandez PhD3, Jose M Lopez Pedrosa PhD4, Helen Murphy 7 
MD5, Ricardo Rueda MD, PhD4, Lucilla Poston PhD1 8 
 9 
1 Department of Women and Children’s Health, King’s College London, 10th 10 
Floor North Wing, St. Thomas’ Hospital, London SE1 7EH, UK 11 
2 Abbott Nutrition, 3300 Stelzer Road, Columbus, OH 43219, USA 12 
3 SEPLIN Statistical Solutions, Granada, Spain 13 
4 Abbott Nutrition, Strategic R&D, 68 Camino de Purchil, Granada 18004, 14 
Spain 15 
5 University of Cambridge Metabolic Research Laboratories, Level 4, Box 289, 16 
Addenbrooke’s Hospital, Cambridge, CB2 0QQ, UK 17 
 18 
Corresponding author: Dr Rahat Maitland, The Queen Elizabeth University 19 
Hospital Glasgow, Scotland. (+44-7974940221) rahatmaitland@nhs.net 20 
 21 
Funding was provided by Abbott Nutrition, Research and Development, 22 
Granada, Spain. 23 
 24 
Keywords: diabetes, pregnancy, obesity, glycaemic index 25 
(ABSTRACT) word count: 248  26 
 27 
Background: Obesity is a risk factor for gestational diabetes. Low glycaemic 28 
index diets attenuate hyperglycaemia. We designed a study to determine 29 
whether a slow-digesting low-glycaemic load (SD-LGI) beverage improves 30 
glucose tolerance in obese pregnant women without gestational diabetes 31 
(GDM). 32 
 33 
Methods: This was a 3-arm comparison study comparing the effects of a SD-34 
LGL nutritional beverage (glycaemic load [GL] 730), an isocaloric control 35 
beverage (GL 1124) and habitual diet on glycaemia in obese pregnant 36 
women. Sixteen women (mean BMI 37kg/m2) were recruited at 24-28 weeks’ 37 
to receive either the SD-LGL or eucaloric control beverage. This was 38 
consumed with breakfast and as a mid-afternoon snack over 2 days with a 39 
controlled diet. Following a 2-day washout period of habitual diet, women 40 
completed 2 days on the alternative beverage with controlled diet. A 10h fast 41 
preceded each intervention phase. 24h glucose was measured using 42 
continuous glucose monitoring. 43 
 44 
Results: Consumption of the lower glycaemic load beverage was associated 45 
with improved measures of glycaemia, compared to the control beverage and 46 
habitual diet at different time periods. Glucose estimates for control v SD-LGI 47 
at 24h (0.23mmol/l [0.16 to 0.31], p<0.001), daytime (0.26mmol/l [0.18 to 48 
0.34], p<0.001) and night time (0.05mmol/l [-0.01 to 0.11] (p=0.09). Post-49 
prandial glucose (PPG) was lower after breakfast but not after dinner, 50 
compared to the control beverage (0.09mmol/l [0.01 to 0.18], p=0.03).  51 
 52 
Conclusion: A slow digesting low glycaemic nutritional beverage may facilitate 53 
improved glucose control in obese pregnant women. To address potential 54 
benefit for clinical outcomes, a randomised controlled trial is warranted. 55 
 56 
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 74 
Introduction 75 
 76 
Obese women have a 2-4 fold increased risk of developing gestational 77 
diabetes (GDM) 1 and maternal body mass index (BMI) is recognized as the 78 
strongest potentially modifiable predictor of GDM 2. Aberrant glucose 79 
homeostasis is evident even amongst obese pregnant women who do not 80 
meet the most rigorous of criteria for GDM diagnosis; in these, continuous 81 
glucose monitoring (CGM) has revealed a delayed and greater post-prandial 82 
peak glucose concentration (at 1h and 2h) 3, 4. Fasting and post-prandial 83 
glucose concentrations are also positively associated with greater fetal fat 84 
mass in infants of obese women without GDM 5.  85 
 86 
Rising rates of obesity combined with lower glucose thresholds for diagnosis 87 
of GDM as recommended by the International Association of Diabetes 88 
Pregnancy Study Groups (IADPSG), World Health Organisation (WHO) and 89 
American Diabetes Association (ADA) has led to a tripling of incident cases 6, 90 
7 necessitating a review of traditional therapeutic approaches to the 91 
prevention and management of GDM. 92 
 93 
Throughout pregnancy, obese women have greater concentrations of plasma 94 
insulin, triglycerides (TGs) and free fatty acids (FFAs) compared to lean 95 
controls, contributing to the multifactorial common pathway of insulin 96 
resistance 5. Thus dietary strategies designed to reduce these biomarkers and 97 
postprandial hyperglycaemia from an early stage in obese pregnant women 98 
provide a novel and logical approach to improve glucose control and avoid 99 
adverse pregnancy outcomes. 100 
 101 
Data from two systematic reviews are inconclusive to support universal 102 
recommendation of low glycaemic index (LGI) diets to prevent or treat GDM 103 
but have yielded important information regarding the safety of the approach 8, 104 
9. Overall, pregnancy outcomes in LGI dietary RCTs have been unchanged 105 
but reported maternal benefits include reductions in gestational weight gain 10, 106 
adiposity 11, plasma glucose concentration 10 and progression to insulin 107 
therapy 12.  108 
 109 
In this study, we undertook a proof of principle, 3-arm randomised comparison 110 
study in obese pregnant women without GDM to evaluate the effects of a 111 
slow-digesting low glycaemic load (SD-LGL) beverage on measures of 112 
glycaemic control using continuous glucose monitoring (CGM) and selected 113 
biomarkers implicated in the pathogenesis of insulin resistance. Comparison 114 
was made to a control beverage composed of rapidly digesting carbohydrate 115 
CHO and habitual diet.  116 
  117 
RESEARCH DESIGN AND METHODS 118 
 119 
Subjects and recruitment 120 
Obese pregnant women (BMI≥30Kg/m2) with a singleton pregnancy and no 121 
history of GDM attending antenatal clinics at Guy’s and St. Thomas’ NHS 122 
Foundation Trust, London, UK, were recruited at 24+0-28+6 weeks’ gestation, 123 
prior to routine 75g oral glucose tolerance test (OGTT) at 28 weeks’.  124 
Exclusions included any dietary intolerance, eating disorder and medical 125 
conditions known to independently influence weight, body composition or 126 
biochemistry. To exclude undiagnosed type 2 diabetes or impaired fasting 127 
glycaemia (IFG) subjects were excluded if fasting plasma glucose was 128 
≥6.1mmol/l at first visit. Ethical approval was granted by the Riverside 129 
Research Ethics Committee, London, UK (Integrated Research Applications 130 
System [IRAS]: 12/LO/0307).  An online database was designed and managed 131 
by Medscinet® (www.medscinet.net).  132 
 133 
A preliminary study was performed to examine the glycaemic effect 134 
(determined by incremental area under the curve [iAUC]) and assess the 135 
palatability of 2 SD-LGL beverages (71.6% of total CHO) compared to a 136 
eucaloric control composed of rapid digesting CHO (100% of total CHO) in 4 137 
categories of women (n=10 per group): lean non-pregnant (BMI ≥18.5-138 
≤24.9kg/m2), obese non-pregnant (BMI ≥30kg/m2), lean pregnant (pre-139 
pregnancy BMI ≥18.5-≤24.9kg/m2) and obese pregnant (pre-pregnancy BMI 140 
≥30kg/m2). The beverage selected for this study achieved the lowest glucose 141 
iAUC and greatest palatability scores across all groups of women (see 142 
Appendix).  143 
 144 
Pre-study visit and randomisation 145 
Subjects were naïve to CGM technology thus a pre-study visit including a trial 146 
wearing the sensor (Abbott FreeStyle® Navigator, Alameda, CA, USA) was 147 
undertaken. Computerised randomisation, using the SQL Server 148 
Randomisation function integrated in the online study database was adopted 149 
and concealed until the study day.  150 
 151 
Study Protocol 152 
This was a 3-arm randomised comparison design. Study visits were held in a 153 
clinical research facility (CRF) equipped with a metabolic kitchen, a research 154 
dietician and physician. The study was performed over 6 consecutive days 155 
divided into three 48h periods with CRF visits on days 1 and 5: 156 
• Days 1- 2 test/control beverage 157 
• Days 3-4 habitual diet 158 
• Days 5-6 test/control beverage 159 
 160 
Preparation instructions for test days included example menus for a 30-50g 161 
CHO meal with overnight fast from 2200h.  162 
 163 
All meals and snacks including the nutritional beverages (packaged in 164 
standard drink cartons) for days 1-2 and 5-6 were provided.  Women were 165 
advised to consume their normal diet during the washout period with no 166 
restriction to physical activity levels.  167 
 168 
Empty food packets and drink cartons were returned and a food and physical 169 
activity diary completed. This was reviewed with the dietician at each CRF 170 
visit.  171 
 172 
Day 1-2. Following CGM calibration and fasting venous blood sampling, the 173 
prescribed breakfast and test/control beverage were consumed, and venous 174 
sampling then carried out every 15 minutes for 3.5h. The importance of 175 
adherence to the controlled diet until midnight on day 2 was reiterated.  176 
 177 
Day 3-4. The habitual diet was adopted until 2200h on day 4, after which 178 
participants fasted in preparation for day 5. 179 
Day 5-6. The prescribed breakfast and the beverage (cross over: control if 180 
previously test, test if previously control) were consumed with venous 181 
sampling as above at the CRF. The controlled diet together with the 182 
test/control beverage was consumed until midnight on day 6.  183 
 184 
Subjects were excluded from data analysis if non-adherence to the controlled 185 
diet was identified from CGM downloads (n=3).  186 
  187 
Dietary Protocol  188 
Macronutrient composition and caloric value were equivalent for the test and 189 
control beverage (percentage total energy (%E) CHO 60.7%, fat 20.8%, 190 
protein 18.5%; total energy and 303Kcal/8oz carton/24-h) (Table 1), in line 191 
with dietary recommendations from the American Diabetes and Heart 192 
Associations for prevention of diabetes and reduction of cardiovascular risk in 193 
non-pregnant subjects 13, 14. The concentration of CHO sub-groups, known to 194 
affect absorption differed significantly, with the test product composed of more 195 
slow-digesting, low-GL carbohydrates (SG-LGL) (72% v 0%), less rapid 196 
digesting CHO (8.4% v 100%), resistant starch (16.3%) and indigestible fiber 197 
(3.7%). The glycaemic load (GL) of the test and control beverages was 730 198 
and 1124 respectively. 199 
 200 
Beverages were provided in 8oz (237ml) cartons; 4oz consumed with 201 
breakfast and 4oz as an afternoon snack (1500h). Addition of the nutritional 202 
beverage to the controlled diet did not exceed recommended daily energy 203 
requirements for the gestational age range of participants (24h total calorie 204 
content 2014kcal inclusive of beverage) 15.  205 
 206 
A standardised diet with a low residue and medium dietary GI reflecting the 207 
“average UK diet” 16 was provided for the two 48 hour controlled periods (days 208 
1-2 and day 5-6). On days 1 and 5, breakfast and lunch were provided in the 209 
CRF with remaining food and study beverages measured out by research 210 
staff. Women were advised to eat at similar times on each day.  211 
Menu choices developed by the research dietician using standard food tables 212 
and WISP® (Tinuviel) dietary software are supplied in the appendix. 213 
 214 
Continuous Glucose Monitoring 215 
The CGM sensor was inserted on day 1 (0800h) and replaced on day 5 216 
(0800h). Mandatory calibrations (1, 2, 10, 24 and 72h) were performed using 217 
the inbuilt capillary glucometer and interstitial glucose measured every 10 218 
minutes for the duration of the study. For analysis of post-prandial glucose 219 
(PPG) glucose response, subjects were required to enter all meal times into 220 
the receiver, excluding the washout period when habitual data was recorded. 221 
CGM data was downloaded using the CoPilot® Health Management System 222 
(Abbott Diabetes Care, Alameda, CA USA) and checked by 2 diabetes 223 
physicians. 224 
 225 
Plasma analyses 226 
Plasma insulin and C-peptide were measured at 15 time points (0-3.5h) and 227 
analysed using manual ELISA kits (Mercodia, Uppsala, Sweden). Plasma 228 
triglyceride and non-esterifed fatty acid (NEFA) concentrations were 229 
measured in plasma samples (0, 60, 120, 180, 210 min) using a clinically 230 
validated automated platform (Clinical Analyser ILab 650, Instrumentation 231 
Laboratories, Warrington, UK) using IL Triglyceride and Randox (FA115) kits.  232 
 233 
All standards, controls and samples were assayed in duplicate and quality 234 
control (QC) was performed. The inter-assay coefficient of variation for all 235 
assays was <5%. Analyses were performed on previously unthawed EDTA 236 
and samples stored -80°C. Technical staff were blinded to the identity of the 237 
samples. 238 
 239 
Analysis and Statistical power  240 
Linear mixed model regression method including trigonometric terms up to 241 
order k=3 was employed in the CGM data analysis to take into account the 242 
high intra-day variability and non-linear structure of CGM data. A linear mixed 243 
model (LMM) assuming a normally distributed error term was fitted to the 244 
data. Further addition of a random effect within the model to take into account 245 
study period (hospital v home) and randomisation were assessed using the 246 
likelihood ratio test. CGM data was analysed in clinically relevant time periods 247 
for each 48h test phase as follows: 24h (0630h-0630h), daytime (0630h to 248 
2350h), night-time (0000h to 0620h [one night only]), fasting blood glucose 249 
(0600h to 0650h [one day only]) and post-prandial (1h, 2h and 3h after the 250 
meal marker).   251 
 252 
Logarithmic transformations were performed for insulin and C-peptide only, 253 
following standard distributional checks. 254 
 255 
All analyses were carried out at a 5% significance level using SPSS version 256 
19 & Stata, version 11.2 (StataCorp, College Station, Texas) and 95% 257 
confidence intervals were obtained for the estimates.  258 
 259 
The study protocol recommended that 22 subjects be 260 
randomised, conservatively assuming a correlation of no more than 0.3 261 
between repeated measurements of glucose. However, as initial analyses 262 
demonstrate a correlation of 0.7, a decision was made to recruit 16 subjects, 263 
giving a power of 96% to detect a difference in glucose between test and 264 
control beverage with 95% confidence (p<0.05). 265 
 266 
Results 267 
Analysis was performed with data from 16 subjects randomised to receive the 268 
test or control beverage at the first visit [(BMI 37kg/m2, range 31-46, SD 4.7) 269 
(age 31 years, range 21-39, SD 4.8)]. Twelve were of Black ethnicity, 2 White 270 
European and 2 of unclassified ethnicity. Three subjects were excluded from 271 
analysis: 2 for non-adherence to the controlled diet (n=2) and 1 who was 272 
unable to wear the sensor.   273 
 274 
When considering the overall performance of the supplement throughout the 275 
study period (2 days and one night), the glucose curve derived from the LMM 276 
was lower than both habitual diet and control periods as shown in (Figure 1A). 277 
Glucose estimates for habitual diet and control days were significantly greater 278 
(p<0.001 for both) (Table 2). 279 
 280 
Estimates of 24h mean glucose concentration for study day 1, 2 and 5 were 281 
lower for the test beverage compared to the control.  On the final day, day 6, 282 
no difference was found (day 1: 4.56 v 4.68 mmol/l, p<0.001, day 2: 4.75mmol 283 
v 4.84mmol/l, p=0.001, day 5: 4.47 v 4.73, p<0.001 and day 6: 4.72 v 284 
4.78mmol/l, p=0.51).  285 
Predicted mean blood glucose concentrations were consistently lower for the 286 
test beverage throughout the day (Figure 1B), with the estimates for the 287 
habitual diet (0.25mmol/l [0.19 to 0.31], p<0.001) and control beverage 288 
(0.04mmol/l [0.18 to 0.34], p<0.001) being significantly greater than the test 289 
beverage (Table 2). No difference was observed between glucose estimates 290 
measured in the CRF versus home study days (-0.02mmol/l [-0.08 to 0.04], 291 
p=0.54).  292 
 293 
Review of CGM downloads in association with the food diaries indicated lack 294 
of adherence to the protocol, with uncontrolled food consumption after 295 
midnight on the 2nd night of each 48h test period. This data was excluded 296 
and analysis of nocturnal data included the 1st night only (day 1 and day 5). 297 
No difference was observed overnight between the test and control beverages 298 
overnight (p=0.09) but glucose concentrations were significantly greater 299 
during the habitual period compared to the test beverage overnight (p<0.001) 300 
(Table 2) (Figure 1C). 301 
 302 
Analysis of fasting glucose (0600-0650h) demonstrated a reduction in glucose 303 
estimates until 0620h (before breakfast) for the test, control and habitual 304 
phases, with a progressive rise thereafter (Figure 1D). Fasting CGM 305 
concentrations recorded over this 50 minute period were significantly lower for 306 
the test beverage compared to the habitual period (p<0.001) but no different 307 
to the control (p=0.22) (Table 2). 308 
 309 
Postprandial data (up to 3h) excluded the habitual washout period since 310 
women were not requested to record meal markers. Glucose concentration 311 
was significantly lower following consumption of the test beverage at 312 
breakfast only (p=0.03) (Table 2). Postprandial glucose (PPG) concentrations 313 
were generally lower on hospital days in the CRF compared to the second 314 
day at home for all meals in both arms (breakfast p<0.001, lunch p=0.80 and 315 
dinner p=0.43) (Table 2).  316 
 317 
Linear regression analysis found no detectable effect of the test beverage 318 
compared to control for concentrations of plasma insulin, C-peptide and TGs 319 
(Table 3). A marginally higher concentration of plasma NEFA was observed 320 
following the test supplement (difference in arithmetic means 0.05 [95%CI 321 
0.00 to 0.10], p=0.049).  322 
 323 
Conclusion 324 
 325 
We tested two dietary beverages of identical macronutrient composition as 326 
part of a calorie-controlled diet in obese pregnant women considered to be at 327 
high risk of GDM. The supplements differed only by CHO composition (Table 328 
1).  329 
 330 
Using CGM, we demonstrated that consumption of a SD-LGL beverage, 331 
specifically developed for use in pregnancy, significantly reduced glucose 332 
concentration over a 24 hour period in addition to day and night periods when 333 
examined separately, compared to habitual living (p<0.001 for all).  334 
 335 
Numerous factors including meal composition, pre-meal glucose 336 
concentration, physical activity, insulin secretion, gastric emptying and hepatic 337 
glucose metabolism determine post-prandial glucose (PPG). Hence, the 338 
reduction in PPG observed following traditional CHO restriction, may be 339 
explicable only in part by the lower total CHO load. Since the rate of gastric 340 
emptying is delayed by fat, the observed increase in percentage energy from 341 
fat to approximately 45% following traditional dietary strategies recommended 342 
by the American College of Obstetricians and Gynaecologists 17, will 343 
undoubtedly influence PPG concentration 18. We demonstrated improvements 344 
in PPG concentrations without a reduction in CHO load or increase in 345 
percentage of energy from fat, excluding this mechanism as a confounder and 346 
thus supporting an independent role of CHO modification. Importantly in this 347 
obese population, the addition of the nutritional supplement to the controlled 348 
diet did not exceed recommended daily energy requirements for the 349 
gestational age period studied 15.  350 
 351 
Consensus methodology for the calculation of GI, requires the measurement 352 
blood glucose 120 minutes after food consumption.19 Recent use of CGM in 353 
GI studies has revealed potential limitations of this long-standing approach. 354 
Following the consumption of mixed meals, Chlup et al. confirmed changes in 355 
glycemia exceeding 120 minutes with a prolonged return to baseline glucose 356 
at 210 minutes and beyond 20. In this study we evaluated the effect of the 2 357 
beverages on PPG to 180minutes. With the advantage of this minimally 358 
invasive approach, inclusion of CGM in future dietary studies may yield 359 
important novel information on the impact of different food groups on PPG.   360 
 361 
Post-prandial glucose was significantly lower following the test beverage 362 
compared to the control and habitual diet at breakfast. Clinically, this presents 363 
the most challenging period to achieve adequate glycaemic control for women 364 
with diabetes in pregnancy due to the physiological secretion of insulin 365 
counter-regulatory hormones coupled with high concentrations of processed 366 
CHO contained in breakfast foods 21. This often results in the use of higher 367 
insulin doses, associated with greater risks of hypoglycaemia or the practice 368 
of excluding CHO from the meal entirely, a potentially challenging option 369 
typically resulting in greater fat consumption. Increased concentrations of 370 
maternal TGs and NEFA, correlated with dietary intake, are strong predictors 371 
of excess fetal fat accretion 5, 22, therefore therapeutic interventions utilising 372 
resistant or LGL CHO to attenuate postprandial hyperglycaemia, which also 373 
limit dietary fat, may have a role not only in the management of diabetes in 374 
pregnancy but also in obese non-diabetic pregnant women who have a 2-5 375 
fold increased risk of delivering a large for gestational age (LGA) infant 23.  376 
 377 
Obese pregnant women are at increased risk of lipotoxicity and its metabolic 378 
sequelae. This occurs as a consequence of increased hydrolysis of dietary 379 
TGs and expanded adipose depots generating FFAs, contributing to insulin 380 
resistance 24, 25. Low GI and GL diets may therefore be more effective in 381 
obese compared to lean women as they are likely to be more insulin resistant 382 
26, 27.  383 
 384 
Most adequately powered studies comparing responses to dietary advice, 385 
designed to increase the consumption of low GI foods in women with 28-31 and 386 
without GDM 10, 29, have been carried out in women with BMI 24-27kg/m2 with 387 
equivocal results. Moses et al., reported improved obstetric outcomes (birth 388 
weight, ponderal index and incidence of LGA) comparing LGI to a “high-fibre 389 
moderate-to-high GI (HGI)” diet in healthy women without GDM (n=62, mean 390 
BMI 25.5kg/m2, mean GI 51 v 58 for LGI and HGI respectively) but did not 391 
replicate these findings in a larger RCT (mean BMI 24.5kg/m2) 29, 32. In both 392 
studies a relatively small albeit significant reduction in GI was achieved in the 393 
intervention arm compared to the control with a greater GI point difference 394 
reported in the former 29, 32.  395 
 396 
Of those dietary advice intervention studies undertaken in women of a higher 397 
BMI, the ROLO study (Low glycaemic index diet in pregnancy to prevent 398 
macrosomia RCT) (mean BMI 26.8kg/m2) reported a reduction in GL and 1h 399 
glucose following a 50g glucose challenge test 10. In the heterogeneous 400 
overweight and obese population of the LIMIT trial (n=2212) (The effects of 401 
antenatal dietary and lifestyle advice for women who are overweight or obese 402 
on maternal diet and physical activity), a lifestyle intervention designed to 403 
reduce LGA infants in overweight and obese women, general dietary advice 404 
led to a small reduction in the GL but no change in the primary outcome or 405 
GDM, although the number of infants with macrosomia was reduced 33. A 406 
reduction in GDM, the primary outcome, was also not met in the exclusively 407 
obese UPBEAT study (mean BMI 36.3kg/m2) but, GI and GL were reduced in 408 
the intervention group as was consumption of CHO, total fat, saturated fat and 409 
total energy. Daily intake of fibre and protein was increased, and gestational 410 
weight gain and maternal adiposity were significantly less at the time of the 411 
oral glucose tolerance test and over the entire pregnancy 11.   412 
Considering the potential therapeutic benefits of low GI and GL diets in 413 
pregnancy, improving glycaemic control using a low GI beverage in high-risk 414 
obese women to attenuate glucose intolerance warrants further exploration. 415 
Current UK National Institute for Health and Care Excellence (NICE) 416 
recommendations include general dietary advice for all obese pregnant 417 
women at the 1st clinical consultation (nice.org.uk/guidance/ph27) and the 418 
most recent economic evaluation of non-pharmacological approaches to 419 
weight management outside of pregnancy reported lower costs associated 420 
with dietary compared to physical interventions 34. This advice is generalised 421 
and at present not adopted across the UK; pragmatically, therefore, we would 422 
recommend habitual diet and activity as the control in future studies of LGI 423 
diets in pregnancy as opposed to specific dietary recommendations for 424 
‘healthy eating’.  425 
Using a similar design as in the present investigation, Hernandez et al. 426 
conducted a study to determine whether reducing the fat content of a complex 427 
carbohydrate traditional ‘GDM’ diet in obese pregnant women with GDM 428 
would improve glucose control, using CGM in controlled and free living 429 
environments 35.  No difference in mean glucose between the lower and 430 
control higher fat diets were observed but the glucose AUC was significantly 431 
greater in those on the lower fat diet for daytime and 24-hour periods. The 432 
clinical relevance of the increase in glucose exposure reported, together with 433 
the modest reductions observed in our study on pregnancy outcomes, 434 
requires assessment. We found no difference following the SD-LGL beverage 435 
in the concentration of relevant biomarkers (plasma insulin, C-peptide and 436 
TGs) but a small increase in NEFA. It would be of interest in future studies to 437 
determine whether glucose-independent pathways contributing to insulin 438 
resistance, as assessed by a targeted metabolome are influenced by this 439 
dietary intervention 36.  440 
Limitations of the study include the small sample size and short duration. This 441 
was a proof of concept study and we would recommend future studies of the 442 
SD-LGI beverage extend until delivery and include evaluation of neonatal 443 
outcomes. It is unclear whether the small reduction in glucose estimates 444 
observed, would correspond to a clinically significant reduction in HbA1c or 445 
adverse neonatal outcomes including macrosomia but analysis of alternative 446 
measures of glycaemia utilising CGM is warranted.  447 
 448 
We recruited a high number of women from Black ethnic minorities who are 449 
recognised to have a significantly greater risk of GDM and type 2 diabetes 450 
compared to White European women of equivalent BMI 37. It is possible that 451 
reductions in glucose observed may not be as pronounced in a Caucasian 452 
population. Conversely, the results indicate that those at greatest risk of GDM 453 
may stand to gain the greatest benefit, as suggested by Louie et al. 30. OGTT 454 
was not performed at recruitment therefore in the absence of biochemical 455 
evidence of glucose intolerance, “high risk for GDM” was defined by BMI on 456 
entry in keeping with similar LGI studies in pregnancy.  457 
Participation in dietary studies may introduce a degree of bias or confounding 458 
as a consequence of the “observer” or “Hawthorn effect,” when individual 459 
behaviours are modified in response to an awareness of being observed. In 460 
this study however, the greatest differences in glycaemia were observed 461 
between the test beverage with controlled diet and habitual diet for all time 462 
periods examined suggesting that diet was not specifically modified on the 463 
habitual days.  464 
The CONCEPTT study demonstrated improvements in maternal glycaemia 465 
and neonatal outcomes in women with T1DM who used CGM 38. It is possible 466 
that CGM plus dietary advice in this high risk obese population may improve 467 
maternal glycaemia or reduce progression to GDM but to the best of our 468 
knowledge there are no studies specifically examining this.    469 
Glucose concentrations were generally lower on the 1st day compared to the 470 
2nd of each 48h test period for both beverages.  Visits on these days were 471 
conducted in the CRF, a highly controlled environment, with limited ability to 472 
exercise.  This could indicate issues with non-adherence to the prescribed 473 
diet on “home” days or could reflect a chance finding although several 474 
methods to improve compliance were adopted: participants being requested 475 
to return all empty food packets/drink cartons and complete a food and 476 
exercise diary.  477 
In conclusion, we have demonstrated in obese women at high risk of GDM 478 
that consumption of a SD-LGL beverage when compared to habitual diet 479 
reduces glucose concentration over a 24-hour period, and that this includes 480 
differences during both day and night time. In contrast to previously reported 481 
low GI diets in obese pregnant women, the beverage comprised both a low GI 482 
CHO and slow digesting CHO, which could have additive clinical benefit. A 483 
reduction in post-prandial glucose at breakfast is also of particular clinical 484 
relevance. Evaluation of this dietary approach in a RCT to reduce incidence of 485 
GDM in high-risk obese women is justified. 486 
 487 
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